Valiant Laboratories Limited
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The c… Read more
Valiant Laboratories Limited (VALIANTLAB) - Total Assets
Latest total assets as of September 2025: ₹4.25 Billion INR
Based on the latest financial reports, Valiant Laboratories Limited (VALIANTLAB) holds total assets worth ₹4.25 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Valiant Laboratories Limited - Total Assets Trend (2021–2025)
This chart illustrates how Valiant Laboratories Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Valiant Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Valiant Laboratories Limited's total assets of ₹4.25 Billion consist of 48.1% current assets and 52.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 1.2% |
| Accounts Receivable | ₹721.84 Million | 18.0% |
| Inventory | ₹39.89 Million | 1.0% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹1.08 Million | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Valiant Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Valiant Laboratories Limited's current assets represent 48.1% of total assets in 2025, a decrease from 80.8% in 2021.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, down from 3.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 18.0% of total assets.
Valiant Laboratories Limited Competitors by Total Assets
Key competitors of Valiant Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Valiant Laboratories Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Valiant Laboratories Limited generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Valiant Laboratories Limited is currently not profitable relative to its asset base.
Valiant Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.85 | 8.76 | 2.97 |
| Quick Ratio | 2.45 | 8.52 | 2.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹1.26 Billion | ₹ 1.70 Billion | ₹ 998.53 Million |
Valiant Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Valiant Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 17.0% |
| Total Assets | ₹4.01 Billion |
| Market Capitalization | $5.31K USD |
Valuation Analysis
Below Book Valuation: The market values Valiant Laboratories Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Valiant Laboratories Limited's assets grew by 17.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Valiant Laboratories Limited (2021–2025)
The table below shows the annual total assets of Valiant Laboratories Limited from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹4.01 Billion | +16.97% |
| 2024-03-31 | ₹3.43 Billion | +60.91% |
| 2023-03-31 | ₹2.13 Billion | +17.14% |
| 2022-03-31 | ₹1.82 Billion | +71.01% |
| 2021-03-31 | ₹1.06 Billion | -- |